Fox Chase Cancer Center News

PHILADELPHIA (July 10, 2017) – Researchers at Fox Chase Cancer Center have identified the specific ways in which the CCDC170 gene may influence breast cancer risk or progression. The laboratories of Xiaowei Chen, PhD, and Richard A. Katz, PhD, have discovered a function for the CCDC170 protein that suggests a mechanism related to the hallmark changes in cell movement seen in breast cancer.

PHILADELPHIA, (July 5, 2017) – Fox Chase Cancer Center announced the addition of the Discovery™ NM750b Molecular Breast Imaging (MBI) system as a complementary diagnostic tool to detect breast cancer after a questionable mammogram. MBI is now available to help physicians in the Philadelphia area detect early stage cancers even in dense breast tissue. 

​PHILADELPHIA, (June 30, 2017) – Alexander Kutikov, MD, has been appointed the new chief of the Division of Urologic Oncology at Fox Chase Cancer Center. He will assume his new responsibilities on July 1, 2017.

PHILADELPHIA (June 27, 2017) – Analyzing a panel of 25 genes, researchers found mutations in genes associated with increased risk of breast or ovarian cancer in approximately seven percent of women tested through a large commercial laboratory. Depending on the gene, they found increased risk between two- and six-fold for breast cancer and two- and forty-fold for ovarian cancer.

PHILADELPHIA (June 27, 2017) – It is important that all patients who have completed cancer treatment have a wellness plan in place as they transition from treatment to recovery.

Modern Healthcare writes that those on the list “stand out for the scope of their executive responsibilities, personal achievements, innovation and commitment to their communities.”

PHILADELPHIA (June 6, 2017) - It is with great respect that we remember and pay tribute to an admired colleague and friend, a luminary in his field, and a noted figure within Fox Chase Cancer Center’s legacy. We join you in mourning the loss of W. Thomas London, MD, Professor Emeritus, on Saturday, June 3, following an apparent heart attack. He was 85 years old.

PHILADELPHIA (June 2, 2017) - Martin J. Edelman, MD, FACP, chair of Hematology/Oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib at the American Society of Clinical Oncology annual meeting in Chicago. Of the 32 patients evaluated, only two responded to the drug, showing it to be ineffective on its own for patients with squamous NSCLC.